JDJustina Dargvainiene

Justina Dargvainiene

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Justina Dargvainiene has a total of 416 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Autoimmune encephalitis: assay choice, pitfalls and predictive value

    by Justina Dargvainiene, Antje Torge, Kim Kristin Falk, Robert Markewitz, Klaus-Peter Wandinger, Ralf Junker, Frank Leypoldt

    Autoimmune encephalitides are rare, antibody-defined and treatable, and commercial assays have moved their diagnosis from specialised research laboratories into routine practice. Over 11 years in our laboratory the number of antibody analyses rose tenfold and the number of analytes per patient rose by 40 %. The proportion of patients with a positive result nevertheless remained near 6 %. The additional analytes identified no additional patients, and the already low pre-test probability per analyte has fallen further. Written for the laboratory, this review aims to provide practical guidance on raising the overall specificity and predictive value of the final report. It sets out what each assay format can and cannot do, which specimen to trust for which antibody, when a titre carries information, how to handle a result that only one technique supports, and which sample belongs in a referral laboratory. It also covers preanalytics, reader competence, external quality assessment and the regulatory framework for in-house assays. In general, the predictive value of a positive result is set not by the specificity of a single assay but by the whole pathway: serum and cerebrospinal fluid (CSF) read together, positives confirmed by a second technique, discordant findings referred rather than reported, and every result matched against the clinical syndrome. We propose graded levels of diagnostic certainty for common result constellations. In the future, reliable neuronal antibody diagnostics will depend less on new antigens than on disciplined reporting: internal training, consensus reading, quality control and dialogue with the requesting clinician.

  • Open Access

    Kappa Free Light Chain for Diagnosis and Neurofilament Light Chain for Prognosis in Autoimmune Encephalitis

    by Franz Felix Konen, Erda Bucak, Franziska Bachhuber, Justina Dargvainiene, Mar Guasp, Juliette Brenner, Anna Lena Streichert, Dominica Hudasch, Lina Marie Albers, Saskia Räuber, et al.

    Background and ObjectivesReliable biomarkers for autoimmune encephalitis (AE) are limited, and emerging CSF markers are not incorporated into current diagnostic criteria. Prognostic tools remain in...


  • Open Access

    Cross-platform comparison of blood glial fibrillary acidic protein quantification in healthy controls and multiple sclerosis

    by Anne Ladwig, Antje Torge, Kim Kristin Falk, Antonia Dammann, Melanie Schlapkohl, Klarissa Hanja Stürner, Klaus-Peter Wandinger, Robert Markewitz, Ralf Junker, Malte Ziemann, et al.

    Background: Glial fibrillary acidic protein (GFAP) is an astrocyte marker increasingly recognized as a biomarker of disease progression in multiple sclerosis (MS). While highly sensitive assays are available, cross-platform harmonization remains insufficient, limiting routine clinical implementation. Objective: To compare three fully automated GFAP assays, assess their analytical agreement and clinical performance across MS subtypes and healthy controls, and evaluate cross-platform conversion approaches. Methods: Serum samples from 435 individuals (298 healthy controls, 51 relapsing–remitting MS (RRMS), 41 primary/secondary progressive MS (PPMS/SPMS)) were analyzed using three automated platforms: Simoa HD-X (Quanterix), Elecsys (Roche), and Lumipulse G600 (Fujirebio). Correlation analyses, Passing–Bablok regression, and Lin's concordance coefficients were applied. Published regression formulas were compared with study-derived equations. Results: Strong correlations were observed across all platforms ( r > 0.90 with outliers; r > 0.95 without; p < 0.001), though minor systematic biases were detected. Progressive MS patients showed significantly higher GFAP concentrations than RRMS and controls. Conversion to a single-platform scale improved agreement, but regression formulas differed substantially from previously published equations. Conclusion: Serum GFAP measurements demonstrate high clinical comparability across automated platforms despite systematic differences in absolute values. Robust harmonization strategies and externally validated conversion models are required before broad implementation in routine MS diagnostics.


  • Open Access

    [ 18 F ]Fluorodeprenyl‐ D2 PET as a Tool to Monitor Disease Activity in GAD65‐Ab Autoimmune Encephalitis

    by Julia S. Dorneich, Jonathan A. Gernert, Hanna Zimmermann, Lisa Tagnin, Marianthi Zeinaki, Laura Sanzo, Letizia Vogler, Elisabeth Kaufmann, Justina Dargvainiene, Frank Leypoldt, et al.

    Objective: To evaluate [ 18 F]fluorodeprenyl‐D2 ([ 18 F]F‐DED) positron‐emission tomography (PET) imaging as a biomarker of disease activity in autoimmune encephalitis (AIE) associated with glutamic acid decarboxylase 65 (GAD65) antibodies. Methods: [ 18 F]F‐DED PET was performed in 25 GAD65‐AIE patients and 8 controls using dynamic (0–60 min) and static (30–60 min) acquisitions. Global astrogliosis was assessed by volumes of distribution (VT; 1‐tissue‐compartment model with carotid input) and standardized uptake values (SUV). Regional cerebellar and mesiotemporal (MT) uptake was normalized to global uptake (SUVr). PET measures were correlated with clinical phenotypes, MRI findings, and serum biomarkers (neurofilament light chain [sNfL], GAD65‐Ab titers, and glial fibrillary acidic protein [sGFAP]). Results: Clinical phenotypes included limbic encephalitis/temporal lobe epilepsy (LE/TLE; n = 17), stiff‐person syndrome ( n = 4), and cerebellar ataxia (CA; n = 4), with overlap in nine patients. Global [ 18 F]F‐DED uptake was higher in patients than controls. VT analysis showed increased cortical and MT uptake, while SUVr analysis demonstrated elevated MT uptake across the cohort. LE/TLE patients exhibited increased MT uptake, and CA patients showed higher cerebellar uptake. [ 18 F]F‐DED uptake did not correlate with sNfL or GAD65‐Ab titers, but sGFAP showed associations with cerebellar and white‐matter uptake. Regional uptake correlated with clinical severity in LE/TLE (MT lobe) and CA (cerebellar white matter). Interpretation: [ 18 F]F‐DED PET reveals region‐specific astrogliosis corresponding to clinical manifestations and disease severity in GAD65‐AIE, supporting its potential as a monitoring tool for disease activity.


  • Open Access

    Comparative analysis of three platforms for serum NfL quantification in healthy controls and MS patients

    by Justina Dargvainiene, Antje Torge, Klaus-Peter Wandinger, Ralf Junker, Robert Markewitz, Pascal Benkert, Eline Willemse, Aleksandra Maleska, Sven Ole Schuster, Malte Ziemann, et al.

    Objectives: Neurofilament light chain (NfL) is a biomarker of neuroaxonal damage in various neurological conditions, including multiple sclerosis (MS). With new analytical platforms entering the market, standardization of serum NfL (sNfL) measurement is essential. This study compared sNfL levels across three assays – NF-light Advantage V2/Plus (Quanterix), Lumipulse G NfL blood (FujiRebio), and Elecsys NfL (Roche Diagnostics) – and derived conversion formulas for harmonization. Methods: Serum samples from three cohorts including healthy donors (n=303) and MS patients (n=181) were analyzed across three platforms. Passing-Bablok regression and correlation analyses assessed inter-platform agreement and potential systematic differences. Assays were further evaluated for their ability to detect MS disease activity. Results: All platforms showed strong correlations (Pearson>0.98; Spearman>0.90, p4 SD) on at least one platform. After excluding outliers, conversion formulas were derived to transform the values to the NF-light Advantage V2/Plus scale: NfL=6.31 × [Elecsys NfL] + 2.33 ng/L; NfL=0.94 × [Lumipulse G NfL] + 1.30 ng/L. In MS patients, all platforms detected significant differences between relapse and remission (p<0.001). Age-adjusted Z scores from converted values yielded the highest effect sizes (Cohen’s d: 0.84 for NF-light Advantage, 1.11 for Elecsys, 0.93 for Lumipulse). Conclusions: The three platforms demonstrated high correlation and comparable performance in sNfL quantification. About 3 % of samples showed strong deviations, highlighting the need for vigilance and further harmonization. Age-adjusted Z scores may enhance clinical and research utility.


  • Open Access

    Risk of Epilepsy and Factors Associated With Time to Seizure Remission in Anti-LGI1 Encephalitis

    by Tobias Baumgartner, Moritz Freyberg, Lucia Campetella, Yvette Crijnen, Justina Dargvainiene, Charlotte Behning, Christian G. Bien, Anna Rada, Harald Prüss, Rosa Rössling, et al.

    Autoimmune encephalitis (AIE) with anti-leucine-rich glioma-inactivated 1 (LGI1) antibodies typically manifests with subacute cognitive deficits, seizures, and psychiatric symptoms, mostly in older adults. Immunotherapy (IT) leads to the cessation of seizures in most patients, yet some develop AIE-associated epilepsy (AEAE) and persistent cognitive deficits. The aim of this large multicentric retrospective observational cohort study was to assess long-term outcomes of patients with anti-LGI1 encephalitis regarding seizures and AEAE and to identify associated factors. We included patients with anti-LGI1 encephalitis from 3 national referral centers/consortia meeting the following inclusion criteria: (I) definite LGI1 limbic encephalitis (Graus criteria); (II) occurrence of seizures; and (III) follow-up period ≥24 months. We aimed to (1) determine the risk of seizure recurrence (ROSR) on remission, (2) investigate clinical and paraclinical biomarkers for an effect on time to seizure remission using Cox proportional hazard modeling (n = 188), and (3) assess the risk of AEAE and determine associated factors (n = 236). AEAE was observed in 5.9% (16/271) of the full cohort. Both AEAE (16/16 vs 129/215, p = 0.001) and longer time to seizure remission (OR 1.36 per year, p = 0.025) were associated with persistent cognitive impairment. Patients with pilomotor seizures had a lower rate of seizure remission (hazard ratio [HR] 0.58, 95% CI 0.55-0.60, p < 0.001) while patients under IT administration had a higher rate of seizure remission over time (HR 12.4, 95% CI 9.67-16.0, p < 0.001). In addition, patients receiving second-line IT tended to achieve earlier seizure remission (log-rank test, p = 0.019). The ROSR at 12, 60, and 120 months on seizure remission was 9% (95% CI 4.5%-13%), 20% (95% CI 11%-28%), and 53% (95% CI 14%-74%), respectively. In conclusion, our results demonstrate that AEAE in anti-LGI1 encephalitis is rare and suggest that the diagnosis of epilepsy is inappropriate in patients reaching seizure remission because of a relatively low ROSR. Accordingly, on seizure remission, the diagnosis of acute symptomatic seizures would be appropriate. Moreover, we validate and quantify the importance of IT for seizure remission and identify biomarkers associated with lower rates of seizure remission. Late remission of seizures and AEAE were associated with persistent cognitive impairment.


  • Open Access

    Neuropathic Pain and Distinct CASPR2 Autoantibody IgG Subclasses Drive Neuronal Hyperexcitability

    by Margarita Habib, Anna-Lena Wiessler, Patrik Fischer, Michele Niesner, Mareike Selcho, Ligia Abrante, Christian Werner, Annemarie Sodmann, Maximilian Koch, Abdolhossein Zare, et al.

    Patients with autoantibodies (aAbs) against the contactin-associated protein-like 2 (CASPR2) suffer from a variety of clinical syndromes including neuropathic pain. CASPR2 is an adhesion protein of the neurexin family and part of the voltage-gated potassium channel complex (VGKC complex) in dorsal root ganglia (DRG) neurons. The pathologic mechanisms following the binding of CASPR2 aAbs and their association with pain are only partially understood. CASPR2 aAbs are mainly of the IgG4 subclass; however, previous studies have neglected subclass-dependent effects. We investigated 49 subclassified patient serum samples positive for CASPR2 aAbs combining superresolution lattice structural illumination microscopy (SIM2) and functional readouts by calcium imaging and electrophysiologic recordings on cultured DRG neurons. CASPR2-positive patient sera subclassified in IgG4 together with at least 1 other IgG subclass (IgGX) and patients with only IgG4 were further subdivided into the pain and no pain groups. A decrease of CASPR2 expression along the axons after exposure to CASPR2 aAbs was observed for all patient groups except the group without pain and IgG4. Moreover, binding of CASPR2 aAbs from patients with pain increased the distance between CASPR2 and associated potassium channels along DRG axons determined by SIM2 microscopy. CASPR2 aAbs of patients with pain significantly increased overall neuronal excitability of cultured DRG neurons as measured by calcium imaging. Patch-clamp recordings revealed significantly decreased current amplitudes of voltage-gated potassium (Kv) channels after incubation with all 4 CASPR2 aAb subclassifications with the most prominent effect of serum samples harboring IgG4 aAbs only. Replacement of patient aAbs by healthy control serum rescued Kv channel function to normal levels suggesting that the affected potassium channel function is due to structural blockage and disrupted interactions within the VGKC complex. The last might also be rescued on novel protein synthesis and membrane trafficking of CASPR2. IgG4 aAbs seem to be the major modifier of potassium channel function. The DRG hyperexcitability is primarily due to impaired Kv channel conductance as a consequence of CASPR2 aAb binding. However, additional unidentified signal pathways contribute to this process in patients with neuropathic pain.


  • Open Access

    Neurofilament Light Chain in Serum and CSF as a Potential Biomarker for Primary Angiitis of the Central Nervous System

    by Christina Krüger, Hans Pinnschmidt, Maximilian Wilmes, Justina Dargvainiene, Frank Leypoldt, Alexander Seiler, Daniela Berg, Tim Magnus, Milani Deb-Chatterji

    Background: Primary angiitis of the central nervous system (PACNS) is a rare vasculitis affecting CNS blood vessels, posing diagnostic challenges due to the limited specificity of the established diagnostic tools. Neurofilament light chain (NfL) might be a promising biomarker in PACNS. Methods: NfL in serum and CSF was measured in 33 PACNS patients (25 active [aPACNS], 8 in remission [rPACNS]) enrolled between 2014 and 2022 and compared to controls (serum: n = 303; CSF: n = 68); Results: Serum NfL was significantly elevated in aPACNS (median: 45.77 pg/mL) versus rPACNS (6.68 pg/mL; p < 0.001) and healthy controls (6.05 pg/mL; p < 0.001). Similarly, CSF NfL was significantly elevated in aPACNS (median: 4914.58 pg/mL) compared to rPACNS (301.19 pg/mL; p = 0.002) and controls (262.83 pg/mL; p < 0.001). Serum and CSF NfL were significantly correlated (r = 0.90, p < 0.001). Additionally, an association between elevated NfL and ischemic lesions was observed (serum: r = 0.59, p = 0.006; CSF: r = 0.43, p = 0.032). A subgroup analysis excluding stroke patients still revealed elevated NfL in 90% (CSF) and 50% (serum), with diminishing discriminatory power with older age. Conclusions: NfL holds potential as a biomarker for PACNS, in particular in younger patients.


  • Open Access

    Spectrum of Clinical and Imaging Features of Children With GFAP Astrocytopathy

    by Simon Sommer, Andreas Panzer, Annikki Bertolini, Robert Cleaveland, Vivek Jain, Tugba Kapanci, Ute Derichs, Tobias Geis, Axel Neu, Christa Löhr-Nilles, et al.

    Glial fibrillary acidic protein (GFAP) antibodies (abs) have been described primarily in adults with a spectrum of autoimmune-mediated diseases. In children, data on clinical and neuroradiologic features of children with autoimmune GFAP astrocytopathy are limited. The aim of this study was to describe the clinical and radiologic features in children with GFAP-ab-associated diseases. We retrospectively recruited children from 13 clinical centers between 2020 and 2023 who (1) tested positive for GFAP-ab in serum and/or CSF and (2) of whom a complete clinical and MRI data set was available. We identified and included 15 children (5 girls, 10 boys). The median age at onset was 9.9 years (range: 2-16 years). All children presented with features of AE or meningitis, acute cerebellitis, or transverse myelitis. CSF pleocytosis was common (13/15, median 245 cells/μL), and 13 (87%) of 15 harbored GFAP-abs in their CSF, 8 (53%) of whom did not have detectable GFAP-abs in their serum. MRI was abnormal in 15 (100%) of 15 children: Specific patterns included confluent lesions in the pons or caudate nucleus (11/15; 73%), peri-aqueductal regions (13/15; 87%), and spinal cord (6/10; 60%). 12 children had a favorable outcome (mRS score of </= 1). Two patients died in the acute phase or during follow-up. GFAP-ab-associated diseases encompass a wide spectrum of clinical presentation associated with a particular set of MRI features clearly distinct to other antibody-mediated diseases or MOGAD. We recommend that testing for GFAP-abs in serum and CSF be included in the workup of children with AE, particularly if brainstem involvement occurs.


  • Open Access

    Aβ38 and Aβ43 do not differentiate between Alzheimer's disease and cerebral amyloid angiopathy

    by Justina Dargvainiene, Ulf Jensen‐Kondering, Benjamin Bender, Daniela Berg, Norbert Brüggemann, Charlotte Flüh, Robert Markewitz, Alexander Neumann, Benjamin Röben, Christoph Röcken, et al.

    Differential diagnosis between Alzheimer's disease (AD) and cerebral amyloid angiopathy (CAA) using cerebrospinal fluid (CSF) biomarkers is challenging. A recent study suggested that the addition of A beta 38 and A beta 43 to a standard AD biomarker panel (A beta 40, A beta 42, t-tau, p-tau) to improve the differential diagnosis. We tested this hypothesis in an independent German cohort of CAA and AD patients and controls using the same analytical techniques. We found excellent discrimination between AD and controls and between CAA and controls, but not between AD and CAA. Adding A beta 38 and A beta 43 to the panel did not improve the discrimination between AD and CAA.